Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Cash (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Cash for 3 consecutive years, with -$33.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 9.67% to -$33.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$43.2 million, a 69.33% increase, with the full-year FY2024 number at -$125.3 million, down 3187.66% from a year prior.
  • Change in Cash was -$33.5 million for Q3 2025 at Inhibrx Biosciences, down from -$30.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $144.8 million in Q3 2023 to a low of -$59.4 million in Q4 2023.
  • A 3-year average of -$4.4 million and a median of -$30.0 million in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: crashed 121.08% in 2024, then soared 351.26% in 2025.
  • Inhibrx Biosciences' Change in Cash stood at -$59.4 million in 2023, then grew by 26.37% to -$43.7 million in 2024, then grew by 23.45% to -$33.5 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Change in Cash are -$33.5 million (Q3 2025), -$30.0 million (Q2 2025), and $63.9 million (Q1 2025).